Valuation dashboard for None (GDTC) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number and Earnings Power Value models plus sector comparison against other peers companies.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies.
Analysis Summary
Balance sheet quality for GDTC: current ratio of 5.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Related companies: CLGN · ENLV · LSTA · MTVA · NCNA · NRSN · NRXS
More sections of GDTC: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks